<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>278</serviceExecutionTime><Trial id="225752"><TitleDisplay>The Emprint Ablate and Resect Study in Patients With Metastatic Lung Tumors</TitleDisplay><TitleOfficial>The Emprint Ablate and Resect Study in Patients With Metastatic Lung Tumors (EMPRESS)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02323854</Identifier><Identifier type="Organisational Study">COVEMPR0437</Identifier><Identifier type="Trial Acronym">EMPRESS</Identifier></Identifiers><Indications><Indication id="3668">Metastatic lung cancer</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Emprint ablation system</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>surgical resection</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1097361" type="Company"><TargetEntity id="5043331632" type="organizationId">Medtronic PLC</TargetEntity></SourceEntity><SourceEntity id="3668" type="ciIndication"><TargetEntity id="10050017" type="MEDDRA"/><TargetEntity id="615" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="1097361">Medtronic plc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>15</PatientCountEnrollment><DateStart>2015-01-31T00:00:00Z</DateStart><DateEnd type="actual">2017-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-14T01:05:33Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Lifespan-Rhode Island Hospital, Rhode Island, USA</Affiliation><Name>Damian E Dupuy, MD FACR</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient or authorized representative has provided informed consent&lt;/li&gt;&lt;li&gt;Patient is &gt;/= 18 years of age&lt;/li&gt;&lt;li&gt;At least one pulmonary metastasis&amp;lt;/= 3.0 cm in maximum diameter resulting from distant primary cancers or at least one recurrence of primary lung cancer &amp;lt;/= 3.0 cm in maximum diameter&lt;/li&gt;&lt;li&gt;Patient has been confirmed by a thoracic surgeon to be a surgical candidate for resection of the tumor targeted for ablation&lt;/li&gt;&lt;li&gt;Patient is willing and able to comply with all aspects of the treatment and evaluation schedule: 2 cm of tumor-free lung parenchyma between target tumor and pleura or fissure&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Pre-procedure exclusion criteria&lt;/li&gt;&lt;li&gt;Contraindicated for surgery&lt;/li&gt;&lt;li&gt;Prolonged chest infection, defined as lung consolidation that requires hospitalization and &gt; 10 days of antibiotics 30 days prior to surgery&lt;/li&gt;&lt;li&gt;Tumor abutting main stem bronchus, main pulmonary artery branches,  esophagus and/or trachea&lt;/li&gt;&lt;li&gt;Tumor with pleural contact&lt;/li&gt;&lt;li&gt;Tumors located&amp;lt; 3 cm of staple lines or other metal objects&lt;/li&gt;&lt;li&gt;Patients diagnosed with GOLD etage III or IV emphysema&lt;/li&gt;&lt;li&gt;Uncontrollable coagulopathy (ie,  international normalized ratio&amp;gt; 1.8 or platelet count &amp;lt; 70,000/microl)&lt;/li&gt;&lt;li&gt;Patients unable to tolerate discontinued use of anti-coagulants prior to and during the ablation procedure&lt;/li&gt;&lt;li&gt;Patient is pregnant (documented by a positive pregnancy test according to hospital standard practices) or is actively breast-feeding&lt;/li&gt;&lt;li&gt;Patient has participated in an investigational drug or device research study within 30 days of enrollment that would interfere with this study&lt;/li&gt;&lt;li&gt;The investigator determines that participation in the study may jeopardize the safety or welfare of the patient&lt;/li&gt;&lt;li&gt;Patients with implantable pacemakers and other electronic implants, in accordance with instructions for use (IFU)&lt;/li&gt;&lt;li&gt;Incidental intraprocedural finding that the patient no longer meets the study eligibility criteria&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Dose response: dose response was assessed by comparing actual ablation zone size and volume to predicted ablation zone size and volume prescribed by the physician using the Emprint Procedure Planning Application. Dose response was measured for each ablation zone using CT imaging immediately post ablation and prior to the surgical resection</Description><Timeframe>1 day</Timeframe></Measure><Measure><Description>Ablation Zone Shape: ablation width (X) / height (Y), ratio of 1 indicates spherical ablation zone shape</Description><Timeframe>Same day</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of Participants With Complete or Incomplete Tumor Ablation: the secondary endpoint was complete tumor ablation immediately post-procedure for each target tumor using histologic analysis. Complete ablation was defined as 100% nonviable tumor cells</Description><Timeframe>Same day</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a post-market, prospective, non-randomized, single-arm, multicenter study, designed to      demonstrate dose response of an ablation system using a percutaneous approach in patients      with metastatic or recurrent primary lung tumors.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive ablation of lung tumor (using Emprint device); followed by surgical resection of the ablation zone.  Percutaneous antenna would be placed into the target tumor under CT image guidance. Target tumor would be ablated. The antenna would be removed and the planned surgical resection of the lung tumor would be conducted as scheduled post ablation procedure.&lt;/para&gt;&lt;para&gt;Primary endpoint would be dose response as indicated by CT imaging, measurement of maximum diameter      and volume. Secondary endpoint would be assessment of complete tumor ablation immediately post-procedure.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>University Hospital Frankfurt</Name><Address1>Frankfurt</Address1><Address3>60590</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Mayo Clinic</Name><Address1>Rochester</Address1><Address2>Minnesota</Address2><Address3>55905</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>Rhode Island Hospital</Name><Address1>Providence</Address1><Address2>Rhode Island</Address2><Address3>02903</Address3><CountrySubDivision code="RI">Rhode Island</CountrySubDivision><Contacts/></Site><Site><Name>Weill Cornell Medical College</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10065</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lung tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3623">Subjects with Advanced Stage Lung Cancer</PatientSegment><SubSegments><SubSegment id="3634">Subjects with metastatic/stage IV lung cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3638">Subjects with Resectable/Operable Lung Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3650">Subjects with Recurrent/Relapsed Lung Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02323854</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lung tumor" id="8515"><Endpoint>Assessment of Other Measures of Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Lung tumor" id="8576"><Endpoint>Assessment of Tumor Related Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Lung tumor" id="8577">Tumor volume assessment</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Lung tumor" id="8651"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lung tumor" id="8588"><Endpoint>Assessment of Biopsy/Cytology/Histology</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lung tumor" id="3910"><Criterion>Subjects with Primary Lung Cancer</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3913"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4091">Subjects with protocol specified tumor size</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3925"><Criterion>Subjects with Protocol Specified Stages of Lung Cancer(TNM staging)</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3936">Subjects with stage IV lung cancer</SubCriterion><SubCriterion disease="Lung tumor" id="3938">Subjects with advanced stage lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3967"><Criterion>Subjects with Resectable/Operable Lung Cancer</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3988"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3993">Subjects with history of/scheduled for anti-cancer surgery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="4000"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Lung tumor" id="34344"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="32043">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="34925"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4074">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lung tumor" id="5193"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5236"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5291"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Lung tumor" id="5344"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5356">Subjects with tumors in close proximity of/ eroding major vessels/vital structures</SubCriterion><SubCriterion disease="Lung tumor" id="5365">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20281"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5176">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="20282"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Lung tumor" id="24918"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="5263">Subjects with contraindications to surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lung tumor" id="25573"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="6757">Subjects with history of/current participation in other clinical trials</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-03-13T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2017-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>25.03 Months</EnrollmentPeriod><EnrollmentRate>0.60 Patients/Month</EnrollmentRate><DateFirstReceived>2014-12-13T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-05-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-03-16T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-01-31T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="283012"><TitleDisplay>The early outcomes and late survival after everolimus-eluting stents versus multiple arterial grafting in patients with multivessel coronary artery disease using a single center institutional database</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="80">Coronary artery disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Everolimus-eluting stent</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Multiple arterial graft</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20544" type="Company"><TargetEntity id="4296787325" type="organizationId">University of Bristol</TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"/><TargetEntity id="D003327" type="MeSH"/><TargetEntity id="-1572475765" type="omicsDisease"/><TargetEntity id="221" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20544">University of Bristol</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Small molecule</Category><Category>Medical device</Category></TrialCategories><PatientCountEnrollment>3787</PatientCountEnrollment><PatientCountEvaluable>3787</PatientCountEvaluable><DateChangeLast>2017-05-15T16:00:30Z</DateChangeLast><DateAdded>2017-01-02T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with mulitvessel coronary artery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Compare early outcomes and late survival after everolimus-eluting stents versus multiple artery grafts</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study would aim to compare early outcomes and late survival after everolimus-eluting stents versus multiple arterial grafting in patients with multivessel coronary artery disease using a single center institutional database [&lt;ulink linkType="Reference" linkID="1888331"&gt;1888331&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In September 2016, results were published. The two groups were comparable for 30-day mortality (1.6 versus 0.8% in the EES and MAG group respectively, p = 0.38). There  was no  stroke  in EES group and it was 0.8% in the MAG group (P=0.13).  The primary coronary intervention was associated with a higher risk of late death after a mean follow-up of 3.1 years (p = 0.01) [&lt;ulink linkType="Reference" linkID="1888331"&gt;1888331&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;A count of 696 patients (18.3%) underwent percutaneous coronary intervention with everolimus-eluting stents and 3091 (81.7%) coronary artery bypass grafting with multiple arterial grafts. With the use of propensity-score matching, 483 pairs were identified for final comparison  [&lt;ulink linkType="Reference" linkID="1888331"&gt;1888331&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-01-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="285878"><TitleDisplay>Cardiac Output and Other Hemodynamic Changes With Prone Position in Cervical Myelopathy Patients Undergoing Surgery</TitleDisplay><TitleOfficial>Cardiac Output and Other Hemodynamic Changes With Prone Position in Cervical Myelopathy Patients Undergoing Surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03027817</Identifier><Identifier type="Organisational Study">NIMHANS</Identifier></Identifiers><Indications><Indication id="2920">Spinal cord disease</Indication></Indications><BiomarkerNames><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2089" role="Therapeutic effect marker" type="Physiological">Cardiac Output</BiomarkerName><BiomarkerName id="2095" role="Therapeutic effect marker" type="Physiological">Mean arterial pressure</BiomarkerName><BiomarkerName id="2263" role="Therapeutic effect marker" type="Physiological">Vascular resistance</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="9438" role="Therapeutic effect marker" type="Physiological">Stroke volume</BiomarkerName><BiomarkerName id="10919" role="Therapeutic effect marker" type="Physiological">Cardiac Index</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>prone positioning</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>surgery</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1047201" type="Company"><TargetEntity id="5035546574" type="organizationId">National Institute Of Mental Health And Neuro Sciences</TargetEntity></SourceEntity><SourceEntity id="2920" type="ciIndication"><TargetEntity id="10061367" type="MEDDRA"/><TargetEntity id="D013118" type="MeSH"/><TargetEntity id="-1096918096" type="omicsDisease"/><TargetEntity id="176" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1047201">National Institute of Mental Health and Neuro Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2014-11-30T00:00:00Z</DateStart><DateEnd type="actual">2015-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-10-11T19:20:43Z</DateChangeLast><DateAdded>2017-01-24T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>National Institute of Mental Health and Neuro Sciences, Bangalore</Affiliation><Name>Nitin Manohar, MD, DNB, DM</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Cervical myelopathy patients undergoing surgery in prone position with:&lt;ul&gt;&lt;li&gt;ASA Class I , II and III&lt;/li&gt;&lt;li&gt;Age between 18 to 65 years&lt;/li&gt;&lt;li&gt;Nurick's grade &gt;/= 2&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Atlanto occipital dislocation and cervicomedullary junction pathology&lt;/li&gt;&lt;li&gt;Tumor pathology&lt;/li&gt;&lt;li&gt;Diabetic patients&lt;/li&gt;&lt;li&gt;Patients positioned prone in the awake state (without induction of anaesthesia)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean arterial pressure: analysis of change in mean arterial pressure at following time points - before induction of anesthesia, 2 min after anaesthetic induction, 2 min after intubation, before turning prone, immediately after turning prone and every 5 min thereafter till 20 min after positioning</Description><Timeframe>Before induction of anesthesia to 20 min after prone positioning (end of study)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Cardiac output: analysis of change in cardiac output at following time points - before induction of anesthesia, 2 min after anaesthetic induction, 2 min after intubation, before turning prone, immediately after turning prone and every 5 min thereafter till 20 min after positioning</Description><Timeframe>Before induction of anesthesia to 20 min after prone positioning (end of study)</Timeframe></Measure><Measure><Description>Heart rate: analysis of change in heart rate at following time points -before induction of anesthesia, 2 min after anaesthetic induction, 2 min after intubation, before turning prone, immediately after turning prone and every 5 min thereafter till 20 min after positioning</Description><Timeframe>Before induction of anesthesia to 20 min after prone positioning (end of study)</Timeframe></Measure><Measure><Description>Stroke volume: analysis of change in stroke volume at following time points -before induction of anesthesia, 2 min after anaesthetic induction, 2 min after intubation, before turning prone, immediately after turning prone and every 5 min thereafter till 20 min after positioning</Description><Timeframe>Before induction of anesthesia to 20 min after prone positioning (end of study)</Timeframe></Measure><Measure><Description>Stroke volume variation: analysis of change in stroke volume variation at following time points - before induction of anesthesia, 2 min after anaesthetic induction, 2 min after intubation, before turning prone, immediately after turning prone and every 5 min thereafter till 20 min after positioning</Description><Timeframe>Before induction of anesthesia to 20 min after prone positioning (end of study)</Timeframe></Measure><Measure><Description>Total peripheral resistance: analysis of change in total peripheral resistance at following time points -before induction of anesthesia, 2 min after anaesthetic induction, 2 min after intubation, before turning prone, immediately after turning prone and every 5 min thereafter till 20 min after positioning</Description><Timeframe>Before induction of anesthesia to 20 min after prone positioning (end of study)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was to evaluate cardiac output and other hemodynamic changes with prone position in cervical myelopathy patients undergoing surgery. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This prospective, observational study would be conducted on 30 patients with cervical myelopathy      who underwent surgery in prone position at NIMHANS, Bangalore hospital. The non invasive      cardiac output monitor (NICOM, Cheetah Medicals) would be used to record various hemodynamic      parameters. The hemodynamic parameters would be recorded at baseline, post induction, post      intubation, prior to prone position, post prone position, and every 5 min thereafter      upto 20 min. Noninvasive cardiac output monitoring parameters would be recorded before and after prone positioning.&lt;/para&gt;&lt;para&gt;The hemodynamic parameters that would  be recorded using the NICOM monitor includes: HR-heart rate (beats /min), NIBP-non invasive blood pressure (mmHg), MAP-mean arterial pressure (mmHg), CO-cardiac output (l/min), CI-cardiac index (l/min/m2), SV-stroke volume (ml/beat), SVV-stroke volume variability (percentage) and TPR-total peripheral resistance (dynes.s/cm5).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other neurological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17728">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="15858">Subjects with spinal cord disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03027817</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other neurological disease" id="43051"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other neurological disease" id="43548"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other neurological disease" id="43436"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Other neurological disease" id="43549">Assessment of heart rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="44220"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other neurological disease" id="45172"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other neurological disease" id="32685"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="33132"><Criterion>Subjects with spinal cord disease (Myelopathy)</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="34204"><Criterion>Subjects with Protocol Specified Age Characteristics</Criterion></Inclusion><Inclusion disease="Other neurological disease" id="34308"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other neurological disease" id="24024"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other neurological disease" id="27919"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other neurological disease" id="24149">Subjects unwilling/unable to comply with the study protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-01-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-01-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="293773"><TitleDisplay>The effect of exercise and extract Nettle on obesity</TitleDisplay><TitleOfficial>The effect of aerobic exercise ergometer with the consumption extract of Nettle on the Nesfatin-1 and C-reactive protein values in overweight and obese women</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2016022324394N2</Identifier><Identifier type="Secondary Organisational">IR.ZAUMS.REC.1394..388</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="418" role="Therapeutic effect marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="419" role="Therapeutic effect marker" type="Anthropomorphic">Waist to Hip Ratio</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="9815" role="Therapeutic effect marker" type="Anthropomorphic">Hip circumference</BiomarkerName><BiomarkerName id="10646" role="Therapeutic effect marker" type="Genomic">Nucleobindin-2</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Nettle extract based therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>aerobic exercise</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1144852" type="Company"><TargetEntity id="5054883776" type="organizationId">University of Sistan and Baluchestan</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1144852">University of Sistan and Baluchestan</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>48</PatientCountEnrollment><DateStart>2015-12-01T00:00:00Z</DateStart><DateChangeLast>2017-04-12T16:01:02Z</DateChangeLast><DateAdded>2017-04-18T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Zahedan University of Medical Sciences</Affiliation><Email>mkarajibani@yahoo.com</Email><Name>Mansour Karajibani</Name><Phone>00989153414358 00</Phone></Contact><Contact type="Scientific contact"><Affiliation>Zahedan University of Medical Sciences</Affiliation><Email>mkarajibani@yahoo.com</Email><Name>Mansour Karajibani</Name><Phone>00989153414358 00</Phone></Contact><Contact type="Public contact"><Affiliation>Zahedan University of Medical Sciences</Affiliation><Email>mkarajibani@yahoo.com</Email><Name>Mansur Karajibani</Name><Phone>00989153414358 00</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Female&lt;/li&gt;&lt;li&gt;Age between 25 to 45 years&lt;/li&gt;&lt;li&gt;Lack of any history of cardiovascular disease, arthritis&lt;/li&gt;&lt;li&gt;Do not use herbal medicines&lt;/li&gt;&lt;li&gt;Lack of regular exercise&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Use of herbal medicines except nettle&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Breastfeeding&lt;/li&gt;&lt;li&gt;Risk of disease&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Nesfatin-1: Kate Nesfatin-1</Description><Timeframe>Before the intervention. Immediately after the intervention</Timeframe></Measure><Measure><Description>CRP: Kate CRP</Description><Timeframe>Before the intervention. Immediately after the intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>BMI: weight/height to the power of 2</Description><Timeframe>Before the intervention. Immediately after the intervention</Timeframe></Measure><Measure><Description>Blood pressure: manometers</Description><Timeframe>Before the intervention. Immediately after the intervention</Timeframe></Measure><Measure><Description>Heart rate: thermometers Polar heart rate</Description><Timeframe>Before the intervention. Immediately after the intervention</Timeframe></Measure><Measure><Description>Waist to hip ratio: waist circumference/hip circumference</Description><Timeframe>Before the intervention. Immediately after the intervention</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the trial is to study the effect of aerobic exercise ergometer with the consumption extract of Nettle on the Nesfatin-1 and C-reactive protein values in overweight and obese women. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This will be a randomized, single-blind trial (participants), placebo-controlled, single-center study. A total of 48 participants will be randomized into four groups. Time : 11 January 2016 till 5 March 2016&lt;br/&gt;Intervention group 1: participants will undergo aerobic + extract. Participants must daily for 2 months, 8 ml of nettle extract solved, in a glass of water after meals to consume. It should be noted that extract essential oils from medicinal plants Gorgan is provided.&lt;br/&gt;Intervention group 2: Extract. Participants will receive  daily for 2 months, 8 ml of nettle extract solved, in a glass of water after meals to consume. It should be noted that extract essential oils from medicinal plants Gorgan is provided.&lt;br/&gt;Control group 1 : participants will undergo aerobic + placebo supplementation.&lt;br/&gt;Control group 2 : participants will receive   placebo supplementation.&lt;br/&gt;Study will carry out a sealed envelope method.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Olympic Village of Zahedan city</Name><Address1>zahedan</Address1><Address2>sistan and baluchestan</Address2><CountrySubDivision>sistan and baluchestan</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Soheila Moghadam Eftekhari</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2016022324394N2</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20524"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20536">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20538"><Endpoint>Assessment of Biomarkers</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20585"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20786">Assessment of heart rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20599"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20554">Assessment of blood pressure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint><SubEndpoint disease="Obesity" id="20403">Assessment of waist to hip ratio</SubEndpoint><SubEndpoint disease="Obesity" id="20404">Assessment of waist-hip circumference</SubEndpoint><SubEndpoint disease="Obesity" id="20405">Assessment of BMI</SubEndpoint><SubEndpoint disease="Obesity" id="20726">Assessment of height</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19790"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19799">Subjects with sedentary lifestyle</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15315"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Obesity" id="15325"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15332">Subjects co-morbid with inflammatory disease</SubCriterion><SubCriterion disease="Obesity" id="15333">Subjects with joint problems</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15353">Subjects on prohibited medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="24974"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15397">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2015-12-06T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>0.19 Months</EnrollmentPeriod><EnrollmentRate>252.63 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-04-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="295330"><TitleDisplay>Genetic Influences Between Cognitive Function and BMI</TitleDisplay><TitleOfficial>Shared Genetic Influences Between Cognitive Function and Body Mass Index (BMI) in the Texas Twin Project</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03116334</Identifier><Identifier type="Organisational Study">H-37801</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Disease marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="12058" role="Disease marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Disease marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20534" type="Company"><TargetEntity id="5035456284" type="organizationId">Baylor College of Medicine</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20534">Baylor College of Medicine</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Cohort</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>869</PatientCountEnrollment><DateStart>2009-09-30T00:00:00Z</DateStart><DateEnd type="actual">2016-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-04-20T16:00:32Z</DateChangeLast><DateAdded>2017-04-21T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;All participants in the TTP database with executive functioning and BMI data, without a parent-reported medical disorder affecting growth&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Parent-reported medical disorder affecting growth More than one sibling in the dataset (if triplets are present, only two randomly selecting siblings will be included)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Executive functioning: this measure will be derived from a computerized test battery incorporating the animal stroop, stop signal, mickey (an anti-trail making, local-global, plus-minus, digit span backward, symmetry span, listening recall, 2-back, keeping track, and running memory for letters tasks. A latent factor of variance common to all these tasks will be used to indicate 'higher order executive functioning'</Description><Timeframe>2 h</Timeframe></Measure><Measure><Description>Body mass index: heights and weights were measured by trained study personnel and BMI will be calculated as weight in kilograms (kg) divided by height in centimeters (cm) squared</Description><Timeframe>10 min</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Academic achievement: this was assessed using the Woodcock-Johnson-III calculations and passage comprehension tests</Description><Timeframe>30 min</Timeframe></Measure><Measure><Description>General cognitive ability: this was assessed using the WASI-II</Description><Timeframe>1 h</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In this study the investigators would  interrogate an existing data set to examine whether      genetic variants would contribute to an inverse association between weight status and cognitive      function. The hypothesis of the investigators was that body mass index (BMI) was inversely related to      a number of variables measuring cognitive function, and that  this inverse relation was at least partially attributable to genetic variants which would influence both BMI and      cognition.&lt;/para&gt;&lt;para&gt;The      specific aims were:&lt;br/&gt;To examine the association between BMI and executive functioning (EF) in a sample of           869 twin children, ages 7 to 15 years old, who had participated in the Texas Twin Project           (TTP). &lt;br/&gt;To gauge the specificity of EF-BMI relations relative to academic achievement and           general cognitive abilities.&lt;br/&gt;To examine the relative contribution of genetic and environment influences to the           inverse association between BMI and EF.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Investigators would be using  existing data collected as part of the Texas Twin Project (TTP) which would consist of  twins and higher-order multiples previously recruited from the Houston and Austin Metropolitan areas, via flyers, the internet (study website) and contact through public school rosters. &lt;br/&gt;Investigators would use information from the known extent of genetic and      environmental sharing between members of MZ (monozygotic; identical) and DZ (dizygotic;      fraternal) twin pairs to quantify the genetic correlation between measures of cognition and      BMI using biometric genetic modeling under the assumptions of the classical twin model. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Children's Nutrition Research Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03116334</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2016-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-04-12T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-04-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="299466"><TitleDisplay>Preoperative Anxiety's Incidence and Related Factors in Surgical Patients</TitleDisplay><TitleOfficial>Preoperative Anxiety's Incidence and Related Factors in Surgical Patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03162692</Identifier><Identifier type="Organisational Study">XYFY2017-KL021-01</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication><Indication id="25">Anxiety disorder</Indication></Indications><BiomarkerNames><BiomarkerName id="8999" role="Disease marker" type="Biochemical">Catecholamines</BiomarkerName><BiomarkerName id="10811" role="Disease marker" type="Biochemical">Prostaglandins</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1083396" type="Company"><TargetEntity id="5038038513" type="organizationId">Xuzhou Medical University</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="25" type="ciIndication"><TargetEntity id="10057666" type="MEDDRA"/><TargetEntity id="D001008" type="MeSH"/><TargetEntity id="-1384065283" type="omicsDisease"/><TargetEntity id="30" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1083396">Xuzhou Medical University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>2000</PatientCountEnrollment><DateStart>2017-04-01T00:00:00Z</DateStart><DateEnd type="estimated">2018-02-01T00:00:00Z</DateEnd><DateChangeLast>2017-06-02T09:12:49Z</DateChangeLast><DateAdded>2017-05-29T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>liujindong1818@163.com</Email><Name>Jindong Liu, M.S</Name><Phone>+86-13951355136</Phone></Contact><Contact type="Scientific contact"><Affiliation>The Affiliated Hospital of Xuzhou Medical University</Affiliation><Name>Jindong Liu, M.S</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age 18 to 70 years old&lt;/li&gt;&lt;li&gt;Sign that informed consent is willing to participate in the study&lt;/li&gt;&lt;li&gt;Education: primary school and above&lt;/li&gt;&lt;li&gt;A 1 days after elective general anesthesia surgery&lt;/li&gt;&lt;li&gt;ASA score grade I to III&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Emergency surgery&lt;/li&gt;&lt;li&gt;Severe mental illness patients (such as anxiety, depression, schizophrenia, etc)&lt;/li&gt;&lt;li&gt;Taking anti-anxiety or antidepressants (benzodiazepines, tricyclic antidepressants, selective serotonin inhibitors, monoamine oxidase inhibitors, etc)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Anxiety level: as measured by STAI (state-trait anxiety questionnaire)</Description><Timeframe>All patients are evaluated one day before surgery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>VAS pain score: as measured by visual smileys scale</Description><Timeframe>At 3, 6, 24, and 48 h after surgery</Timeframe></Measure><Measure><Description>Blood inflammation index: extraction of patients with arterial blood to laboratory tests</Description><Timeframe>Extraction of arterial blood before anesthesia induction</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study      is to determine the incidence of preoperative anxiety and related predictors, and to      evaluate the effect of anxiety on anesthesia and postoperative pain and prognosis. The study      also showed that prostaglandin, catecholamines, cortex effects of alcohol and inflammatory      cell level on postoperative pain in patients with preoperative anxiety.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 2000 patients undergoing elective general anesthesia in surgery in Xuzhou Medical University patients will be included and observed in this study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>The Affiliated Hospital of Xuzhou Medical University</Name><Address1>XuZhou</Address1><Address2>Jiangsu</Address2><Address3>221000</Address3><CountrySubDivision>Jiangsu</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>liujindong1818@163.com</Email><Name>Jindong Liu, M.S</Name><Phone>+86-13951355136</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8424">Subjects with Post-Operative Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="15301">Others</PatientSegment><SubSegments><SubSegment id="17337">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03162692</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="44332"><Endpoint>Assessment of Anxiety by Protocol Specified Scales</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="35004">Assessment by Spielberger State-Trait Anxiety Inventory (STAI)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="34860">Assessment of Pain by Visual Analog Scale (VAS)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22142"><Criterion>Subjects with Peri-operative Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22143">Subjects with post operative pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22172"><Criterion>Subjects with Normal/Acceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="22173">Subjects with pre-specified physical status</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22210"><Criterion>Subjects with History/Scheduled for Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="22232">Subjects with history/scheduled to receive general anaesthesia/sedation</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34371"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22263">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34745"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22260">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34827"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22264">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20137">Subjects with history/scheduled to receive anti-depressants</SubCriterion><SubCriterion disease="Pain" id="20147">Subjects with history/scheduled to receive serotonin agonists</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="27926"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="20184">Unwillingness to comply with protocol requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-02-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-05-18T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-05-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="321843"><TitleDisplay>Validation of HaGuide Software Module Accuracy in Mapping STN Boundaries in Parkinsons Disease Patients Who Underwent DBS Procedure</TitleDisplay><TitleOfficial>A Retrospective, Multicenter, Clinical Validation of HaGuide Software Module Accuracy in Mapping Sub-thalamic Nucleus (STN) Boundaries in Parkinsons Disease Patients Who Underwent Deep Brain Stimulation (DBS) Procedure</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03363724</Identifier><Identifier type="Organisational Study">AO-001</Identifier></Identifiers><Indications><Indication id="255">Parkinsons disease</Indication></Indications><BiomarkerNames><BiomarkerName id="21845" role="Disease marker" type="Structural (imaging)">Subthalamic nucleus</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Neuro-Omega system</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>deep brain stimulation</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1037663" type="Company"><TargetEntity id="4297894189" type="organizationId">Alpha Omega Engineering Ltd</TargetEntity></SourceEntity><SourceEntity id="1041987" type="Company"><TargetEntity id="5037100034" type="organizationId">Swedish Medical center HB</TargetEntity></SourceEntity><SourceEntity id="16594" type="Company"><TargetEntity id="5035523660" type="organizationId">Hadassah Medical Organization CC</TargetEntity></SourceEntity><SourceEntity id="25520" type="Company"><TargetEntity id="5035561352" type="organizationId">University of Colorado</TargetEntity></SourceEntity><SourceEntity id="255" type="ciIndication"><TargetEntity id="G20" type="ICD10"/><TargetEntity id="10061536" type="MEDDRA"/><TargetEntity id="D010300" type="MeSH"/><TargetEntity id="-342157116" type="omicsDisease"/><TargetEntity id="127" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1037663">Alpha Omega Engineering Ltd</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1041987">Swedish Medical Center (Colorado)</Company><Company id="16594">Hadassah Medical Organization</Company><Company id="25520">University of Colorado System</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>103</PatientCountEnrollment><DateStart>2016-12-31T00:00:00Z</DateStart><DateEnd type="actual">2017-03-30T00:00:00Z</DateEnd><DateChangeLast>2018-01-09T15:12:19Z</DateChangeLast><DateAdded>2017-12-11T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of Colorado, Denver</Affiliation><Name>John A Thompson, Dr</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient was diagnosed with Parkinsons disease&lt;/li&gt;&lt;li&gt;Patient underwent implantation of DBS electrode in the STN for the treatment of Parkinsons disease, using the Neuro-Omega device for navigation&lt;/li&gt;&lt;li&gt;Procedure MER digital recorded data is available&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;DBS performed for any other movement disorder other than Parkinsons disease including Parkinsonism&lt;/li&gt;&lt;li&gt;The recording has a high intensity of noise that will not allow re-analysis using the HaGuide software, in such cases the HaGuide software indicates that the signal is not valid for analysis&lt;/li&gt;&lt;li&gt;Missing data for primary end-point on the respective patient medical chart&lt;/li&gt;&lt;li&gt;The collected data that is used for the validation is with high step size resolution&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>HaGuide versus neurosurgeon measurements: percent agreement between HaGuide software measurements and expert neurosurgeon/electrophysiologist measurements</Description><Timeframe>2 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>DBS implant optimal track identification: percent agreement in DBS implant optimal track identification by percent agreement between HaGuide and Neurosurgeon choice of optimal track for DBS implant</Description><Timeframe>2 weeks</Timeframe></Measure><Measure><Description>DLOR Entry/exit: entry/exit from DLOR (depth in mm)</Description><Timeframe>2 weeks</Timeframe></Measure><Measure><Description>DLOR versus VMNR: length (mm) of dorso-lateral oscillatory region (DLOR) versus ventro-medial non-oscillatory region (VMNR)</Description><Timeframe>2 weeks</Timeframe></Measure><Measure><Description>STN Length: length of STN track (mm)</Description><Timeframe>2 weeks</Timeframe></Measure><Measure><Description>Sites/users comparison: sub-group analysis to determine the variation between sites by percent agreement between HaGuide software measurements and expert neurosurgeon/electrophysiologist measurements</Description><Timeframe>2 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was to validate HaGuide software module accuracy in mapping sub-thalamic nucleus (STN) boundaries in Parkinsons disease patients who underwent deep brain stimulation (DBS) procedure.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients diagnosed with Parkinsons disease who underwent implantation of DBS electrode in the STN for the treatment of Parkinsons disease, using the Neuro-Omega device for navigation and  whose MER digital recorded data of the procedure  would be available would be included and observed in this study. HaGuide version 1.0 software module would be used to map STN boundaries.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of Colorado, Denver</Name><Address1>Denver</Address1><Address2>Colorado</Address2><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03363724</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Parkinsons disease" id="10208"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Parkinsons disease" id="10211"><Endpoint>Assessment of Brain Structure and Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Parkinsons disease" id="10208"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Parkinsons disease" id="10211"><Endpoint>Assessment of Brain Structure and Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Parkinsons disease" id="10229"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Parkinsons disease" id="10230">Assessment of efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Parkinsons disease" id="10234"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Parkinsons disease" id="6061"><Criterion>Subjects with Diagnosis of Parkinson's Disease by Clinical Criteria</Criterion></Inclusion><Inclusion disease="Parkinsons disease" id="6112"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="6122">Subjects with history of brain surgery</SubCriterion><SubCriterion disease="Parkinsons disease" id="6123">Subjects with history of deep brain stimulation</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Parkinsons disease" id="6150"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Parkinsons disease" id="34905"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="6152">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Parkinsons disease" id="7769"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="25629"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion><Exclusion disease="Parkinsons disease" id="27929"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="7787">Inability to comply with study protocol and/or follow up procedures</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-03-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-11-19T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-12-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="331220"><TitleDisplay>Cervical Length in Cases of Placenta Previa</TitleDisplay><TitleOfficial>Value of Third Trimester Cervical Length Measurement in Predicting Risk and Severity if Antepartum Hemorrhage in Cases of Placenta Previa</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03451136</Identifier><Identifier type="Organisational Study">CAIRO UNIVERSITY OBGYN 14534</Identifier></Identifiers><Indications><Indication id="3401">Placenta disease</Indication><Indication id="552">Bleeding</Indication></Indications><BiomarkerNames><BiomarkerName id="12993" role="Disease marker" type="Structural (imaging)">Cervix</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1043313" type="Company"><TargetEntity id="5035544740" type="organizationId">Cairo University</TargetEntity></SourceEntity><SourceEntity id="3401" type="ciIndication"><TargetEntity id="O43" type="ICD10"/><TargetEntity id="10035132" type="MEDDRA"/><TargetEntity id="D010922" type="MeSH"/><TargetEntity id="-639270342" type="omicsDisease"/><TargetEntity id="2042" type="siCondition"/></SourceEntity><SourceEntity id="552" type="ciIndication"><TargetEntity id="10055798" type="MEDDRA"/><TargetEntity id="D006470" type="MeSH"/><TargetEntity id="-1283225934" type="omicsDisease"/><TargetEntity id="327" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043313">Cairo University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>80</PatientCountEnrollment><DateStart>2018-03-01T00:00:00Z</DateStart><DateEnd type="estimated">2018-07-15T00:00:00Z</DateEnd><DateChangeLast>2018-03-07T11:49:22Z</DateChangeLast><DateAdded>2018-03-07T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Cairo University</Affiliation><Email>Marwameid2014@gmail.com</Email><Name>Marwa Mohamed Eid, PhD</Name><Phone>01001225079</Phone></Contact><Contact type="Public contact"><Email>Hmhaggag@kasralainy.edu.eg</Email><Name>Hisham Mamdouh Haggag, PhD</Name><Phone>01224460134</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age: 20 to 45 years old&lt;/li&gt;&lt;li&gt;Single pregnancy&lt;/li&gt;&lt;li&gt;Fetal gestational age 28 to&amp;lt; 36 weeks&lt;/li&gt;&lt;li&gt;Normal amniotic fluid index (AFI)&lt;/li&gt;&lt;li&gt;Diagnosis of placenta previa by pelvic ultrasound that was confirmed when the lower placental edge overlies the internal cervical os on transvaginal ultrasound (TVS)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Threatened preterm labor and maternal use of vaginal progesterone&lt;/li&gt;&lt;li&gt;Preterm premature rupture of membranes&lt;/li&gt;&lt;li&gt;Polyhydramnios&lt;/li&gt;&lt;li&gt;Presence of cercelage and history of cervical cone biopsy which both affect cervical length&lt;/li&gt;&lt;li&gt;Diagnosis of multiple fetal anomalies&lt;/li&gt;&lt;li&gt;Women with other risk factors for intra-partum hemorrhage&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Cervical length measured in mm in relation to antepartum hemorrhage: to find out the relationship between cervical length measured by transvaginal ultrasound and occurrence of antepartum hemorrhage in cases of placenta previa</Description><Timeframe>4 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Need for blood transfusion: yes or no and no. of packed units</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>Need for cesarean hysterectomy: yes or no</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>Need for neonatal ICU: yes or no</Description><Timeframe>4 months</Timeframe></Measure><Measure><Description>Type of cesarean delivery: elective or emergency cesarean delivery</Description><Timeframe>4 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study establishes the relationship between cervical length and whether it can be used to      predict hemorrhage and preterm delivery in cases of placenta previa. The objective of this study was to establish if there is a relation between transvaginal      ultrasonographic measurement of cervical length in cases of placenta previa and whether it      can be used as a predictor for antepartum hemorrhage or not.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Healthy pregnant females aged between 25 to 40 years will be recruited and observed for the risk and severity of antepartum hemorrhage in cases of placenta previa.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Egypt"><Sites><Site><Name>Cairo University</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other gynecological disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="16679">Others</PatientSegment><SubSegments><SubSegment id="18794">Healthy Subjects</SubSegment><SubSegment id="19116">Pregnant subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="17543">Women  giving birth/Obstetrics</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="18260">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="18740">Subjects with Labor Complications</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03451136</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other gynecological disorder" id="43656"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Other gynecological disorder" id="46372">Assessment of pathological parameters</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Other gynecological disorder" id="46495"><Endpoint>Hematological Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other gynecological disorder" id="46363"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gynecological disorder" id="46455"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Other gynecological disorder" id="46456">Requirement for blood transfusion/transfusion of packed RBCs/Blood product utilization</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other gynecological disorder" id="33094"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gynecological disorder" id="34640"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other gynecological disorder" id="33095">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other gynecological disorder" id="35242"><Criterion>Subjects with History of/Undergoing Specified Procedures</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other gynecological disorder" id="24055"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other gynecological disorder" id="24303"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other gynecological disorder" id="27237"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-07-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-02-05T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-03-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="335664"><TitleDisplay>Impact of Mindfulness Training on Stress-Related Health Outcomes in Law Enforcement</TitleDisplay><TitleOfficial>The Impact of Mindfulness-Based Resilience Training on Stress-Related Biological, Behavioral, and Health-Related Outcomes in Law Enforcement Officers</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03488875</Identifier><Identifier type="Organisational Study">2017-1529</Identifier><Identifier type="Secondary Organisational">2017-R2-CX-0033</Identifier></Identifiers><Indications><Indication id="1936">Acute stress disorder</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="175" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-10</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="554" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-8</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="2534" role="Therapeutic effect marker" type="Biochemical">Hydrocortisone</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName><BiomarkerName id="36136" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytokines</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Madison Mindfulness-Based Resilience Training</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1089461" type="Company"><TargetEntity id="5000025492" type="organizationId">United States Department of Justice</TargetEntity></SourceEntity><SourceEntity id="DOL1000742" type="Company"><TargetEntity id="5000726299" type="organizationId">University of Wisconsin-Madison</TargetEntity></SourceEntity><SourceEntity id="1936" type="ciIndication"><TargetEntity id="F43.0" type="ICD10"/><TargetEntity id="10001084" type="MEDDRA"/><TargetEntity id="D013315" type="MeSH"/><TargetEntity id="-166634484" type="omicsDisease"/><TargetEntity id="37" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="DOL1000742">University of Wisconsin-Madison</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1089461">US Department of Justice</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2018-03-06T00:00:00Z</DateStart><DateEnd type="estimated">2020-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-12-18T09:54:52Z</DateChangeLast><DateAdded>2018-04-11T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>grupe@wisc.edu</Email><Name>Daniel W Grupe, PhD</Name><Phone>608-263-7572</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of Wisconsin, Madison</Affiliation><Name>Daniel W Grupe, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;At least 18 years of age&lt;/li&gt;&lt;li&gt;Capable of giving informed consent&lt;/li&gt;&lt;li&gt;Fluent in English&lt;/li&gt;&lt;li&gt;Currently employed sworn law enforcement officer working in the Dane County Sheriff's Office, Madison Police Department, or&lt;ulink linkType="Company" linkID="DOL1000742"&gt;University of Wisconsin-Madison&lt;/ulink&gt; Police Department&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Extensive prior experience in meditation practice, or previous completion of mindfulness-based stress reduction, mindfulness-based resilience training, or a substantively similar meditation training program&lt;/li&gt;&lt;li&gt;A work schedule that precludes one from committing to regular participation in the 8-week training program&lt;/li&gt;&lt;li&gt;Command staff working in a supervisory role&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in perceived occupational stress: change in combined scores of perceived operational and organizational stressors from the Police Stress Questionnaire (McCreary and Thompson, 2004) from baseline to 3 months. Each of these 2 scales has 20 items with 1-7 ratings, where higher scores indicate greater stress (1=no stress at all, 7=A lot of stress). Organizational and operational stress scales will be summed to create a single value with a range of 40 to 280</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in diurnal cortisol slope: saliva samples collected on each of 3 days will be used to calculate diurnal cortisol slope, defined as the change between the peak cortisol response in the 45 min after awakening and cortisol levels just prior to bedtime, with a hypothesized steeper slope in the intervention versus waitlist group at post-intervention (3 months) versus baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in cortisol awakening response: the cortisol awakening response (CAR) will be measured using saliva samples collected 0, 30, and 45 min after awakening on each of 3 days, with hypothesized increased CAR in the intervention versus waitlist group at post-intervention (3 months) versus baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in hyperarousal symptoms: change in hyperarousal symptoms from the PTSD checklist for DSM-5 at post-intervention (3 months) versus baseline</Description><Timeframe>Baseline, post-intervention (3 months), follow-up (6 months)</Timeframe></Measure><Measure><Description>Change in peripheral inflammatory markers: composite of hsCRP and 4-plex of pro-inflammatory cytokines (IL-6, IL-8, IL-10, TNF-alpha) is hypothesized to be lower in intervention versus waitlist group at post-intervention (3 months) versus baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in subjective sleep quality: global scores on the Pittsburgh Sleep Quality Index (Buysse et al., 1988) will be compared at post-intervention (3 months) versus baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in behavioral pattern separation ability: changes in lure discrimination index (LDI) scores from the Mnemonic Similarity Task (Stark et al., 2015) will be assessed between baseline and post-intervention (3 months). LDI scores have a theoretical range of -1 to +1, where a score of +1 indicates perfect ability to discriminate novel items from those previously seen and 0 indicates chance discrimination of novel from previously seen items. Negative scores, while theoretically possible, are rare as they indicate greater labeling of novel items as 'old' compared to previously seen items as 'old'</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in hair cortisol concentration: hair cortisol concentration will be assessed from a 3 cm sample of hair collected from participants' scalps, corresponding to approximately 3 months of hair growth, at 6 months versus baseline</Description><Timeframe>Baseline, follow-up (6 months)</Timeframe></Measure><Measure><Description>Change in mood and anxiety symptoms: change in depression and anxiety subscale scores from the 43-item version of the Patient-Reported Outcomes Measurement Information System (PROMIS-43) at post-intervention (3 months) versus baseline. There are 6 depression and 6 anxiety items, each of which is scored on a scale of 1 ('never') to 5 ('always'), yielding a range of 6 to 30 for each subscale with higher scores indicating greater impairment</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in restful minutes of sleep: change in minutes of behaviorally assessed restful sleep time during 1 week of sleep measured in the field using Fitbit charge 2 activity trackers at post-intervention (3 months) versus baseline</Description><Timeframe>5 to 7 nights of sleep will be monitored at baseline and post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in perceived stress: changes in total scores from the Perceived Stress Scale (10-item version; Cohen et al., 1988) from baseline to 3 months</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in total PTSD symptoms: change in total PTSD symptoms from the PTSD Checklist for DSM-5 at post-intervention (3 months) versus. baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in resting heart rate: changes in average resting heart rate calculated over 3 to 7 days of field data collection using a Fitbit Charge 2 activity tracker at post-intervention (3 months) vs. baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in pain interference: change in pain interference subscale scores from the 43-item version of the Patient-Reported Outcomes Measurement Information System (PROMIS-43) at post-intervention (3 months) versus. baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in burnout: change in the two core dimensions of burnout, exhaustion and disengagement, on the Oldenburg Burnout Inventory (Halbesleben &amp; Demerouti, 2005) at post-intervention (3 months) versus. baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in work productivity: change in work productivity, measured as the estimated percentage of work time affected by chronic mental and physical health issues on the Work Limitations Questionnaire (short form; Lerner et al., 2001) at post-intervention (3 months) versus. baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in good health practices: change in physical health and well-being behaviors as measured by the Good Health Practices Scale (Hampson et al., 2017) at post-intervention (3 months) versus. baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in self-reported mindfulness: changes in total scores and individual dimensions of the Five-Facet Mindfulness Scale (short form; Bohlmeijer et al., 2011) at post-intervention (3 months) versus. baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure><Measure><Description>Change in work-family spillover: change in work-to-family and family-to-work spillover from the Work-Family Spillover Scale (Grzywacz &amp; Marks, 2000) at post-intervention (3 months) versus. baseline</Description><Timeframe>Baseline, post-intervention (3 months)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, controlled trial of an 8-week mindfulness-based training program for police officers (Madison Mindfulness-Based Resilience Training [mMBRT])&lt;br/&gt;is to investigate the      impact of this training on subjective responses to stress, stress-related psychological and      physical health outcomes, and biological and behavioral correlates of perceived stress. In addition to self-report measures, this study will assesses an array of      objective biological and behavioral outcomes both in the laboratory and in the field that may      speak to mechanisms of change involved in symptom reduction.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 120 police officers will be recruited from Dane County law enforcement agencies to take part      in an 8-week, group-based, mindfulness-based training program called Madison      Mindfulness-Based Resilience Training (mMBRT). &lt;/para&gt;&lt;para&gt;Officers will be randomized to one of the two groups:&lt;br/&gt;Group 1 (active group; experimental): participants will receive mMBRT immediately after baseline assessments. mMBRT will be structurally similar to mindfulness-based stress reduction (MBSR) developed specifically for police officers, which is similar to and inspired by a program developed by researchers at Pacific University (Christopher, Goerling et al., 2016) with 8 weekly 2 h  classes involving guided      meditation practices, gentle movement, and group-based discussion (one of these classes,      toward the end of the course, will be approximately 4 h and integrates many of the practices      and teachings covered throughout the training program). Participants will be provided with      weekly homework assignments and audio recordings that provide guided instruction in various      meditation and yoga practices (participants will be asked to engage in home practice for up to 30 min/day, 6 days/week throughout the intervention).&lt;br/&gt;Group 2 (waitlist control group; no intervention): participants will receive receive mMBRT after a post-intervention assessment and a subsequent      follow-up assessment.  Particpants will complete the same assessments as those in the active treatment group, but will not be offered any intervention until the conclusion of the trial. At this time, control group participants will be offered the intervention.&lt;/para&gt;&lt;para&gt;At three separate timepoints, officers will take part in a laboratory assessment that      involves the following procedures:&lt;br/&gt;Administration of computerized behavioral tasks.&lt;br/&gt;Completion of self-report questionnaires that assess trauma history and occupational           stressors, perceived stress, sleep, physical and mental health.&lt;br/&gt;Collection of a small amount of blood via finger prick and/or venipuncture (to assess           peripheral inflammatory markers).&lt;br/&gt;Collection of a small amount of hair from the scalp (to assess hair cortisol           concentration).&lt;br/&gt;Measurement of height and weight for the assessment of body mass index, and for use with           activity trackers data.&lt;/para&gt;&lt;para&gt;In conjunction with these laboratory assessments, data will be collected from officers in the      field over the course of approximately 1 week (coinciding with a regularly scheduled work      week), including the following procedures:&lt;br/&gt;Officers will wear an activity monitor (eg,  Fitbit) to allow for objective monitoring           of sleep quality and resting heart rate throughout the study.&lt;br/&gt;Officers will collect saliva samples 4 times per day over 3 days for the assessment of           salivary cortisol&lt;br/&gt;Officers will complete daily logs of work hours, types of events encountered during           work, perceived stress related to these events, and self-reported mood and affect           ratings&lt;br/&gt;These field data will be related to dispatch records, which will provide objective      information regarding the types of incidents responded to, and the time and location of these      incidents. The laboratory and field assessments will be collected at baseline (prior to randomization);      after the active mMBRT group completes the intervention; and at a follow-up visit      (approximately 4 months after the end of the intervention), after which the wait-list group      will be offered the intervention.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Center for Healthy Minds, University of Wisconsin-Madison</Name><Address1>Madison</Address1><Address2>Wisconsin</Address2><Address3>53703</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>grupe@wisc.edu</Email><Name>Daniel W Grupe, PhD</Name><Phone>608-263-7572</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Anxiety disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="15222">Others</PatientSegment><SubSegments><SubSegment id="18723">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03488875</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Anxiety disorder" id="10437"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Anxiety disorder" id="46099"><Endpoint>Assessment of Cortisol Levels</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="45783">Salivary Cortisol Levels</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Anxiety disorder" id="10420"><Endpoint>Assessment of Symptoms of Post Traumatic Stress Disorder</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="10424">Assessment by PTSD Checklist [PCL]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anxiety disorder" id="10437"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anxiety disorder" id="10467"><Endpoint>Assessment of Sleep</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="10469">Assessment by Pittsburgh Sleep Quality Index (PSQI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anxiety disorder" id="10477"><Endpoint>Assessment of Co-morbidity</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="10481">Assessment of depression</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Anxiety disorder" id="10490"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Anxiety disorder" id="44563"><Endpoint>Subjects Assessed Based on Protocol Specified Diagnostic Criteria</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Anxiety disorder" id="10390"><Endpoint>Assessment of Anxiety by Protocol Specified Scales</Endpoint></OtherEndpoint><OtherEndpoint disease="Anxiety disorder" id="10452"><Endpoint>Assessment of Neuropsychological Function</Endpoint><SubEndpoints><SubEndpoint disease="Anxiety disorder" id="10458">Assessment of behavior</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Anxiety disorder" id="10483"><Endpoint>Assessment of Vital Signs</Endpoint></OtherEndpoint><OtherEndpoint disease="Anxiety disorder" id="46099"><Endpoint>Assessment of Cortisol Levels</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Anxiety disorder" id="6637"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6653">Subjects able to communicate in the language specified in the protocol</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="34428"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6638">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="34519"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6636">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Anxiety disorder" id="34902"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="6639">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Anxiety disorder" id="8239"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="8252"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Anxiety disorder" id="26738"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Anxiety disorder" id="8254">Subjects unable to comply with study/protocol requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-03-22T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-04-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="374262"><TitleDisplay>GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL</TitleDisplay><TitleOfficial>GDPE/CEOPE Compared With CEOPE as the First-line Therapy for Newly Diagnosed Patients With Peripheral T-Cell Lymphoma</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03884205</Identifier><Identifier type="Organisational Study">GEMCITABINE-PTCL</Identifier></Identifiers><Indications><Indication id="1727">Acute leukemia</Indication><Indication id="1753">Peripheral T-cell lymphoma</Indication><Indication id="1755">Anaplastic large cell lymphoma</Indication><Indication id="1758">Angioimmunoblastic T-cell lymphoma</Indication><Indication id="2867">Panniculitis</Indication><Indication id="311">T-cell lymphoma</Indication><Indication id="599">Intestine disease</Indication></Indications><BiomarkerNames><BiomarkerName id="5700" role="Disease marker" type="Genomic;Proteomic">ALK receptor</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>cis-platinum</Name></Intervention><Intervention type="InterventionPrimary"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionPrimary"><Name>dexamethasone</Name></Intervention><Intervention type="InterventionPrimary"><Name>epirubicin</Name><Drug id="13022">epirubicin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>etoposide phosphate</Name><Drug id="3072">etoposide phosphate</Drug></Intervention><Intervention type="InterventionPrimary"><Name>gemcitabine</Name><Drug id="3199">gemcitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>prednisone</Name></Intervention><Intervention type="InterventionPrimary"><Name>vincristine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="combo"><Interventions><Intervention type="InterventionControl"><Name>cyclophosphamide</Name></Intervention><Intervention type="InterventionControl"><Name>epirubicin</Name><Drug id="13022">epirubicin</Drug></Intervention><Intervention type="InterventionControl"><Name>etoposide phosphate</Name><Drug id="3072">etoposide phosphate</Drug></Intervention><Intervention type="InterventionControl"><Name>prednisone</Name></Intervention><Intervention type="InterventionControl"><Name>vincristine</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="13022">epirubicin</Drug><IndicationsPioneer><Indication id="1727">Acute leukemia</Indication><Indication id="2867">Panniculitis</Indication><Indication id="599">Intestine disease</Indication></IndicationsPioneer><Companies><Company><Company id="1067506">Shandong Provincial Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3072">etoposide phosphate</Drug><IndicationsPioneer><Indication id="2867">Panniculitis</Indication></IndicationsPioneer><Companies><Company><Company id="1067506">Shandong Provincial Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3199">gemcitabine</Drug><IndicationsPioneer><Indication id="2867">Panniculitis</Indication><Indication id="599">Intestine disease</Indication></IndicationsPioneer><Companies><Company><Company id="1067506">Shandong Provincial Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3199" type="Drug"><TargetEntity id="102180" type="siDrug">Gemcitabine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="13022" type="Drug"><TargetEntity id="91069" type="siDrug">Epirubicin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1067506" type="Company"><TargetEntity id="5037337971" type="organizationId">Shandong Provincial Hospital</TargetEntity></SourceEntity><SourceEntity id="1727" type="ciIndication"><TargetEntity id="10000830" type="MEDDRA"/><TargetEntity id="684" type="siCondition"/></SourceEntity><SourceEntity id="1753" type="ciIndication"><TargetEntity id="C84.4" type="ICD10"/><TargetEntity id="10034623" type="MEDDRA"/><TargetEntity id="D016411" type="MeSH"/><TargetEntity id="-585182853" type="omicsDisease"/><TargetEntity id="3114" type="siCondition"/></SourceEntity><SourceEntity id="1755" type="ciIndication"><TargetEntity id="D017728" type="MeSH"/><TargetEntity id="98841" type="ORPHANET"/><TargetEntity id="-1333243149" type="omicsDisease"/><TargetEntity id="2258" type="siCondition"/></SourceEntity><SourceEntity id="1758" type="ciIndication"><TargetEntity id="C86.5" type="ICD10"/><TargetEntity id="200.80" type="ICD9"/><TargetEntity id="10002449" type="MEDDRA"/><TargetEntity id="86886" type="ORPHANET"/></SourceEntity><SourceEntity id="2867" type="ciIndication"><TargetEntity id="10033675" type="MEDDRA"/><TargetEntity id="D015434" type="MeSH"/><TargetEntity id="-1728715738" type="omicsDisease"/><TargetEntity id="3585" type="siCondition"/></SourceEntity><SourceEntity id="311" type="ciIndication"><TargetEntity id="10042971" type="MEDDRA"/><TargetEntity id="D016399" type="MeSH"/><TargetEntity id="-664594417" type="omicsDisease"/><TargetEntity id="704" type="siCondition"/></SourceEntity><SourceEntity id="599" type="ciIndication"><TargetEntity id="D007410" type="MeSH"/><TargetEntity id="-442314948" type="omicsDisease"/><TargetEntity id="1348" type="siCondition"/><TargetEntity id="1849" type="siCondition"/></SourceEntity><SourceEntity id="142" type="Action"><TargetEntity id="419" type="Mechanism">DNA Topoisomerase II Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1067506">Shandong Provincial Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="142">Topoisomerase II inhibitor</Action><Action id="82444">DNA helicase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="50">Anticancer alkylating agent</Class><Class id="750">DNA intercalator</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="66">Antibiotic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="603">Systemic formulation unspecified</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Case Control</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2019-04-01T00:00:00Z</DateStart><DateEnd type="estimated">2020-09-30T00:00:00Z</DateEnd><DateChangeLast>2019-03-25T09:26:37Z</DateChangeLast><DateAdded>2019-03-25T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>yujiejiang05@126.com</Email><Extension>8613370506886</Extension><Name>Yujie MS JIANG, Dr</Name><Phone>8613370506886</Phone></Contact><Contact type="Public contact"><Email>xinw007@126.com</Email><Extension>8613370506886</Extension><Name>Xin Wang</Name><Phone>8613370506886</Phone></Contact><Contact type="Scientific contact"><Affiliation>Shandong Provincial Hospital</Affiliation><Name>Wang Xin</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Peripheral T cell lymphoma, not otherwise specified&lt;/li&gt;&lt;li&gt;Angioimmunoblastic T cell lymphoma&lt;/li&gt;&lt;li&gt;ALK-negative anaplastic large cell lymphoma&lt;/li&gt;&lt;li&gt;Enteropathy associated T cell lymphoma&lt;/li&gt;&lt;li&gt;Subcutaneous panniculitis like T cell lymphoma&lt;/li&gt;&lt;li&gt;Acute T-cell leukemia/lymphoma&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Woman in pregnancy or lactation&lt;/li&gt;&lt;li&gt;Allergic to any intervention drug&lt;/li&gt;&lt;li&gt;Unsuitable to the study due to severe complication&lt;/li&gt;&lt;li&gt;Enrolled to other study during the past 6 months&lt;/li&gt;&lt;li&gt;NK/T lymphoma ALK-positive anaplastic large cell lymphoma&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>RR: response rate (including complete response and partial response)</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>PFS: progression free survival</Description><Timeframe>One year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to      compare the response and survival rate of GDPE/CEOPE (&lt;ulink linkType="Drug" linkID="3199"&gt;gemcitabine&lt;/ulink&gt;, cis-platinum, &lt;ulink linkType="Drug" linkID="3072"&gt;etoposide&lt;/ulink&gt;,      and dexamethasone/cyclophosphamide, vincristine, &lt;ulink linkType="Drug" linkID="13022"&gt;Pharmorubicin&lt;/ulink&gt;, etoposide, and prednisone)      with those of CEOPE (cyclophosphamide, vincristine, Pharmorubicin, etoposide, and prednisone) regimen, looking forward to its superiority in efficacy and safety for      the newly diagnosed adult patients with PTCL (peripheral T-cell lymphoma).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with PTCL will be divided into two groups to receive either GDPE/CEOPE or CEOPE  alone as the first-line therapy strategy.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Yujie MS JIANG</Name><Address1>Jinan</Address1><Address2>Shandong</Address2><Address3>250014</Address3><CountrySubDivision>Shandong</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>yujiejiang05@126.com</Email><Extension>8613370506886</Extension><Name>Yujie M JIANG</Name><Phone>8613370506886</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lymphoma</Disease><PatientSegments><PatientSegment><PatientSegment id="3490">Subjects with T Cell Non Hodgkin's Lymphoma</PatientSegment><SubSegments><SubSegment id="3483">Subjects with anaplastic large cell lymphoma (ALK positive/ALK negative)</SubSegment><SubSegment id="3484">Subjects with angioimmunoblastic T cell lymphoma</SubSegment><SubSegment id="3486">Subjects with enteropathy associated T cell lymphoma (EATL)</SubSegment><SubSegment id="3488">Subjects with peripheral T cell lymphoma (PTCL)</SubSegment><SubSegment id="9948">Subjects with subcutaneous panniculitis-like T cell Iymphoma</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="19048">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3982">Subjects with T-Cell Leukemia</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19052">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03884205</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lymphoma" id="7604"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Lymphoma" id="7563">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Lymphoma" id="7564">Assessment of Partial Response (PR)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="7906"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7907">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Leukemia" id="7908">Assessment of Complete Response</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lymphoma" id="7547"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7891"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Lymphoma" id="7554"><Endpoint>Assessment of Survival</Endpoint></OtherEndpoint><OtherEndpoint disease="Lymphoma" id="7679"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Leukemia" id="7897"><Endpoint>Assessment of Survival</Endpoint></OtherEndpoint><OtherEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lymphoma" id="3465"><Criterion>Subjects with T Cell Non Hodgkin's Lymphoma</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="3458">Subjects with anaplastic large cell lymphoma (ALK positive/ALK negative)</SubCriterion><SubCriterion disease="Lymphoma" id="3459">Subjects with angioimmunoblastic T cell lymphoma</SubCriterion><SubCriterion disease="Lymphoma" id="3461">Subjects with enteropathy associated T cell lymphoma (EATL)</SubCriterion><SubCriterion disease="Lymphoma" id="3463">Subjects with peripheral T cell lymphoma (PTCL)</SubCriterion><SubCriterion disease="Lymphoma" id="7078">Subjects with subcutaneous panniculitis-like T cell Iymphoma</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lymphoma" id="3657"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Leukemia" id="4984"><Criterion>Subjects with Specific Sub-type of Lymphoid Leukemia</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="4988">Subjects with T-cell leukemia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5187"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5413">Subjects with study specific protocol requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="22405"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Lymphoma" id="35109"><Criterion>Treatment Naive Subjects</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lymphoma" id="4702"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4742"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Lymphoma" id="4825"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4831">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Lymphoma" id="4838">Subjects failing to meet protocol specified criteria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Leukemia" id="6596"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Leukemia" id="6706"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6716">Subjects with history of participation in other trial/have received treatment with a drug that has not received regulatory approval</SubCriterion><SubCriterion disease="Leukemia" id="6723">Protocol specified exclusion criteria for females</SubCriterion><SubCriterion disease="Leukemia" id="6726">Subjects not fulfilling eligibility criteria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="25574"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Lymphoma" id="4836">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="25755"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="25404">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Lymphoma" id="26955"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-03-16T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-03-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>